| |
Pharmasset Appoints Michelle Berrey as Chief Medical Officer and William Symonds as Vice President, Clinical Pharmacology
|
| |
| |
Press announcement from Pharmasset
Princeton, NJ - (January 24, 2007) - Pharmasset is pleased to announce
the appointments of M. Michelle Berrey, MD, MPH as Chief Medical Officer
and William T. Symonds, PharmD as Vice President, Clinical Pharmacology.
Dr. Berrey joins us from GlaxoSmithKline, where she most recently served
as Vice President, Viral Diseases, Clinical Pharmacology & Discovery
Medicine. Dr. Symonds also joins us from GlaxoSmithKline, where he most
recently served as Director, Antiviral Clinical Pharmacology & Discovery
Medicine.
Dr. Berrey's experience includes the design, early development, medical
governance, clinical strategy and product life cycle management for
antiviral products, and she has simultaneously managed multiple clinical
trials across all phases of development. Dr. Berrey was most recently
responsible for the early development and clinical strategy of Phase
I-IIa studies for new targets against HIV, hepatitis viruses and hepatic
fibrosis at GlaxoSmithKline. Dr. Berrey received a Master of Public
Health from Emory University, and she received her M.D. from the Medical
College of Georgia. She completed her Internship and Residency in
Internal Medicine at the University of North Carolina, Chapel Hill, and
she was a Senior Fellow in Infectious Disease Medicine at the University
of Washington, Seattle, where she conducted research in HIV transmission
and acute HIV infection.
Dr. Symonds has clinical pharmacology experience in anti-infective and
antiviral drug development, including international drug development and
medical project management from Phases I to IV. He contributed to
regulatory filings for several marketed antiviral compounds and was most
recently involved in the early phase development of several antiviral
programs. Dr. Symonds received his Doctorate of Pharmacy from Campbell
University in North Carolina, and he completed a Fellowship in Clinical
Pharmacokinetics focusing on anti-infective pharmacology at the Clinical
Pharmacokinetics Laboratory at Millard Fillmore Hospital in Buffalo, New
York.
About Pharmasset
Pharmasset is a clinical stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections. Pharmasset's primary focus is on the development of oral
therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C
virus (HCV) and human immunodeficiency virus (HIV).
|
|
| |
| |
|
|
|
